Summary
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products, including Verkazia, which is used for the treatment of vernal keratoconjunctivitis; STN1008903, which is used for dry eye treatment; Eybelis for the treatment of glaucoma and ocular hypertension; Alesion, an anti-allergy ophthalmic solution; Diquas for the treatment for dry eye syndrome; and glaucoma products, such as Tapros, Tapcom, PRESERFLO MicroShunt, and ROCK inhibitor products. The company also developing various pharmaceutical products to treat glaucoma, such as STN1014000, which is in clinical preparation; STN1012600, which is in Phase II clinical trial; STN1011101, STN1013001, and STN1013900, which are in Phase III clinical trial; STN1011402, which is in Phase III clinical trial to treat allergies; STN1010904, which is in Phase II clinical trial to treat fuchs endothelial corneal dystrophy; STN1010905, which is in Phase II clinical trial to treat meibomian gland dysfunction; and STN1013600, which is in Phase I clinical trial to treat presbyopia. In addition, it provides STN1012701, which is in Phase III clinical trial to treat myopia; STN1013800, which is in clinical preparation to treat ptosis; STN6000100, which is in clinical preparation to treat retinitis pigmentosa; STN1013400, which is in Phase I clinical trial to treat myopia; and STN1012700, which is in Phase I clinical trial to treat myopia. Further, it offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.
History
Founded in 1896, Santen has been committed to ophthalmology for more than 120 years. As a specialised global pharma company, Santen is dedicated to therapies for the prevention, treatment and care of diseases of the eye.
Mission
Our goal is to help people around the world to see and experience a brighter future.
Vision
We strive to be a leading global company in ophthalmology in terms of sales, profits, and social contribution.
Key Team
Ms. Kaori Itagaki (Gen. Mang. of Investor Relations Group)
Ms. Mika Masunari (Gen. Counsel & Chief Compliance Officer)
Ms. Nobuko Kato (Chief Communications Officer)
Mr. Satoshi Suzuki (Sr. Corp. Officer & Head of Corp. Devel. Division)
Mr. Shinichi Teramachi (Corp. Officer, Head of Sales Department & Japan Sales and Marketing Division)
Mr. Ippei Kurihara (Corp. Officer and Head of Marketing Department, Japan Bus., Japan Sales & Marketing Division)
Mr. Kenji Morishima (Corp. Officer & Head of China Product Devel. Department)
Recognition and Awards
In 2017, Santen was recognised as one of the Top 100 Companies for Working Families in Japan for the second consecutive year.
References
Japan 